SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing intense volatility driven by a technical short squeeze and heavy concentration of ownership, prompting heated debates among traders over whether the surge is a sustainable momentum play or a manipulated trap. The community is actively tracking institutional filings and options flow while warning of the high-risk, exit-liquidity nature of the current price action.

Beyond Meat, Inc. engages in the provision of plant-based meats. Its products include ready-to-cook meat under The Beyond Burger and Beyond Sausage brands, and frozen meat, namely, Beyond Chicken Strips and Beyond Beef Crumbles. The company was founded by Ethan Walden Brown and Brent Taylor in 2009 and is headquartered in El Segundo, CA.

Beyond Meat Inc

Beyond Meat is driving intense community debate as traders weigh the potential for a massive short squeeze against significant long-term dilution and weak business fundamentals. While the stock's elevated borrow rates and heavy volume have ignited speculation of a parabolic move, many participants remain wary, viewing the surge as a high-risk speculative play driven by retail momentum and intense battle between bulls and bears.

Battalion Oil Corp. is an independent energy company, which engages in the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing significant volatility as investors weigh the potential for a regional energy crisis against ongoing uncertainty surrounding the geopolitical situation in the Middle East. The community is actively debating the impact of potential supply disruptions, dilution concerns, and the credibility of diplomatic headlines while monitoring for a breakout from the stock's current consolidation phase.

Faraday Future Intelligent Electric, Inc. is an emerging growth company, which manufactures electric vehicles. The company was founded by Jia Yueting in May 2014 and is headquartered in Gardena, CA.

Faraday Future Intelligent Electric Inc - Ordinary Shares - Class A

Faraday Future Intelligent Electric Inc

Faraday Future is seeing high retail engagement driven by recent news of a financing agreement and an expansion into embodied AI robotics education, sparking intense debate between traders anticipating a momentum-driven squeeze and skeptics focused on the company's history of dilution and potential reverse stock split.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a significant expansion of its partnership with NVIDIA, which integrates QNX technology into AI-driven robotics and industrial systems. The community is actively debating the stock's transition from a legacy brand to a critical infrastructure provider, fueled by high volume and bullish sentiment surrounding its growing role in physical AI.

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Cytodyn Inc

CytoDyn Inc

CytoDyn is trending as investors gear up for the American Association for Cancer Research (AACR) annual meeting, where the community is focused on upcoming poster presentations for the leronlimab mTNBC and mCRC trials. Bullish sentiment is being driven by anticipation of new clinical data and recent buzz around the potential for leronlimab to serve as a 'universal primer' that enhances the efficacy of existing immunotherapy treatments.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing significant investor interest driven by a combination of positive housing market data, institutional accumulation, and anticipation of upcoming earnings reports. The community is actively debating the stock's potential for a short squeeze, fueled by high short interest and enthusiasm for the company's strategic shift toward vertical integration of mortgage and title services.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as investors aggressively discuss persistent rumors of a potential buyout, fueled by recent hiring activity and comparisons to successful acquisitions within the biotech sector. The community is actively debating the stock's price action and institutional accumulation, with many expressing frustration over the lack of official news despite strong long-term growth prospects.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates potential AI data center partnerships and leadership changes, with many traders closely watching for a breakout amid heavy call option activity and persistent short interest. While bulls highlight the company's power-efficient GaN technology and institutional accumulation, bears remain skeptical, focusing on valuation concerns and recent insider selling activity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is currently navigating intense market volatility driven by its high correlation to Bitcoin's price fluctuations and ongoing speculation surrounding the pending Clarity Act. While some investors are concerned about potential legislative delays and weak price action relative to broader crypto trends, others view the stock as a long-term infrastructure play, pointing to institutional growth and the increasing utility of the company's exchange platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

Altimmune (NASDAQ:ALT) shareholders approved all proposals presented at the company's virtual annual meeting on April 16, 2026, including the election of nine directors and amendments that expand the...

Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the firm, Marketbeat Ratings reports. Two investment...

<ul class="summary-bullets"><li>The average 12-month price target on the stock is $18, representing a potential upside of as much as 495% from the stock’s current $3.02 trading levels.</li><li>The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026.</li><li>Truist believes that pemvidutide "could be successful in treating MASH as well as liver-related diseases AUD."</li></ul>Shares of Altimmune (ALT) traded 5% lower on Friday despite Wall Street viewing a potential upside of as much as 495% on the stock.According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.The average 12-month price target on the stock is $18, compared to the stock’s current $3.02 trading levels.<h2 class="st-heading-2">Wall Street Take</h2>Earlier this month, Truist initiated coverage of Altimmune with a ‘Buy’ rating and $12 price target. The firm believes that the company's lead candidate pemvidutide "could be successful in treating MASH."Truist is modelling peak 20,000 patients on pemvidutide, which would result in worldwide "peak adjusted/unadjusted revenue of ~$600million/$1.0billion," it said.<h2 class="st-heading-2">Altimmune Pipeline</h2>Altimmune is a clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The company’s pemvidutide is in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in addition to MASH.The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026. The trial is expected to evaluate multiple pemvidutide doses over a 52-week treatment period.The company is looking forward to announcing topline data from a mid–stage trial of pemvidutide in Alcohol Use Disorder in the third quarter of 2026, and is also enrolling patients into a mid-stage trial of the drug in Alcohol-associated Liver Disease.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around ALT stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user expressed disappointment about the stock’s downward trajectory.<stembedurl>https://www.stocktwits.com/Moemazon/message/648788986</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 45% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-dives-despite-gene-therapy-approval-wall-street-dismisses-sell-off/cZ3HfqIRImh">RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.

Equity

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.


ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

ALT Pemvidutide Explained: What Makes It Different in MASH

Altimmune's pemvidutide targets MASH with dual glucagon/GLP-1 biology, showing mid-stage promise as it advances toward a high-stakes phase III study.

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning Anti-Aging Protein Research Takes a Step Forward with Cell Cloning PR Newswire VANCOUVER, BC, March 24, 2026 Issued on behalf of Ava...

Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial

Truist Financial initiated coverage on shares of Altimmune in a research note on Wednesday. They issued a "buy" rating and a $12.00 price target on the stock...

What is HC Wainwright's Estimate for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Equities researchers at HC Wainwright raised their Q1 2026 earnings estimates for Altimmune in a report released on Monday, March 16th. HC Wainwright...

HC Wainwright Forecasts Altimmune's Q4 Earnings (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT - Free Report) - Analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Altimmune in a report issued on Monday, March 16th. HC Wainwright...

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Max long

Hedged

Net short

All cash

Stocktwits

Stocktwits Polls

Investors are actively debating the impact of the company's authorized share increase and its potential for suppressing stock price.

Bullish sentiment centers on the unique advantages of Pemvidutide, specifically its potential for MASH treatment and lean muscle preservation.

Anticipation is building around mid-2026 data readouts for AUD, with stakeholders looking for news to break the current trading range.

Traders are intensely scrutinizing option flow and potential market manipulation by institutions pinning the stock price.

Market participants are increasingly calling for a strategic partnership or buyout to gain a competitive edge in the weight-loss space.

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALT News

ALTAltimmune Inc